CNTX Context Therapeutics Inc
5,310
$2.00
$0.20
(11.11%)
| Watchers | 5,310 |
| 52-Wk Low | $0.6001 |
| 52-Wk High | $2.10 |
| Market Cap | $150M |
| Volume | 617,683.00 |
| 52-Wk High | $2.10 |
| 52-Wk Low | $0.6001 |
Context Therapeutics Advances Cancer Trial with FDA SubmissionTipRanks Financial Blog • about 2 months ago
Context Therapeutics (CNTX) has provided an update. Context Therapeutics Inc. has announced the submission of an IND application to the FDA for a P...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ( Context or the Company ) (Nasdaq: CNTX), a...
Context Therapeutics (NASDAQ:CNTX Free Report) had its target price lowered by HC Wainwright from $5.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. HC...
Maxim Group analyst Jason McCarthy maintained a Buy rating on Context Therapeutics (CNTX Research Report) yesterday and set a price target of $4...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations...
Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Context Therapeutics (CNTX Research Report) and Barinthus Biotherapeutics...